In melanoma and bladder cancer models, combining EZH2 inhibitors with anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) therapy demonstrated a direct role for EZH2-mediated T-cell reprogramming in enhancing anti-tumor immunity (54). Here, EZH2 is linked to neoplasm.